<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of the hospitalized adult patient with severe ulcerative colitis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of the hospitalized adult patient with severe ulcerative colitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of the hospitalized adult patient with severe ulcerative colitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Peppercorn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Farrell, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Ulcerative colitis (UC) is a chronic inflammatory condition of the large intestine that is limited to the mucosal layer of the colon. It almost always involves the rectum, and may extend in a proximal and continuous fashion to involve other portions of the colon. The pattern of disease activity is characterized by periods of active inflammation alternating with periods of remission.</p><p>Acute severe UC is a potentially life-threatening condition, and patients are at risk for progressing to bowel perforation or toxic megacolon. In addition, the short- and long-term risk for colectomy is high.</p><p>This topic will review the management of hospitalized patients with acute severe ulcerative colitis. The management of ambulatory, low-risk patients with mild to moderate colitis and the management of ambulatory, high-risk patients with moderate to severe ulcerative colitis are discussed separately. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a> and  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults"</a>.)</p><p>Surgical management of ulcerative colitis is discussed separately. (See  <a class="medical medical_review" href="/d/html/1375.html" rel="external">"Surgical management of ulcerative colitis"</a>.)</p><p>The diagnosis and management of toxic megacolon is discussed separately. (See  <a class="medical medical_review" href="/d/html/1381.html" rel="external">"Toxic megacolon"</a>.)</p><p class="headingAnchor" id="H2505467373"><span class="h1">DEFINING DISEASE SEVERITY</span><span class="headingEndMark"> — </span>Clinical trials of UC often use formal grading systems to describe disease activity. The severity of UC is generally classified as mild, moderate, or severe disease; however, the definition of severe disease activity may vary in the literature depending on the specific index or score being used (eg, Truelove and Witts severity index [<a href="#rid1">1</a>], Mayo Clinic score [<a href="#rid2">2</a>], Montreal classification [<a href="#rid3">3</a>]). (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Disease activity, severity, and risk'</a>.)</p><p>In clinical practice, the following definition of acute severe UC may be more useful [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Bloody stool frequency ≥6 per day</p><p class="bulletIndent1"><span class="glyph">●</span>PLUS at least one of the following characteristics (ie, evidence of systemic toxicity):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fever (temperature ≥37.8 degrees C)</p><p class="bulletIndent2"><span class="glyph">•</span>Tachycardia (heart rate ≥90 beats/minute)</p><p class="bulletIndent2"><span class="glyph">•</span>Anemia (hemoglobin &lt;10.5 g/dL [105 g/L])</p><p class="bulletIndent2"><span class="glyph">•</span>Elevated inflammatory marker (eg, C-reactive protein, erythrocyte sedimentation rate)</p><p></p><p>In addition, a small subgroup of patients may present with (or progress to) fulminant UC, which is characterized by bloody stool frequency ≥10 per day with fecal urgency, often accompanied by abdominal pain and abdominal distension, in addition to the criteria for acute severe UC [<a href="#rid4">4</a>]. (See <a class="local">'Complications'</a> below.)</p><p class="headingAnchor" id="H1133540027"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>When a patient presents with clinical features of acute severe UC, the pretreatment evaluation (ie, laboratory studies, lower endoscopy, imaging) serves to exclude alternative or co-existing conditions and to determine the severity and extent of disease. </p><p>Our approach to diagnostic testing for hospitalized patients with acute severe UC includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory studies -</strong> We initially obtain complete blood count, liver biochemical tests, blood urea nitrogen, creatinine, albumin, total cholesterol, and C-reactive protein (CRP). While CRP as a serologic marker of inflammation has largely replaced erythrocyte sedimentation rate (ESR), both may be sent in combination, and in rare circumstances, clinicians may only have access to ESR [<a href="#rid5">5-7</a>].</p><p></p><p class="bulletIndent1">For patients with fever (temperature ≥37.8 degrees C) or with leukocytosis in the absence of glucocorticoids, we also obtain blood cultures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stool studies</strong> – We typically obtain stool testing for infection (ie, <em>Clostridiodes</em> [formerly <em>Clostridium</em>]<em> difficile</em>, routine stool cultures [<em>Salmonella</em>, S<em>higella</em>, <em>Campylobacter</em>, <em>Yersinia</em>], and specific testing for <em>E. coli</em> O157:H7). For patients with risk factors for parasitic infection (eg, recent travel to a region where parasitic infections are endemic), stool microscopy for ova and parasites (three specimens) and a <em>Giardia</em> stool antigen test are also checked. If feasible, we also favor evaluation for amebiasis with stool antigen testing or stool PCR. Stool analysis for the detection of pathogens is discussed in more detail separately:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis", section on 'Diagnosis'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5723.html" rel="external">"Giardiasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/14001.html" rel="external">"Approach to stool microscopy"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5727.html" rel="external">"Intestinal Entamoeba histolytica amebiasis"</a>.)</p><p></p><p class="bulletIndent1"><em>Clostridiodes</em> (formerly <em>Clostridium</em>)<em> difficile infection </em>(CDI) is common in patients with UC who are acutely ill, and CDI is associated with increased risk of colectomy and mortality [<a href="#rid8">8-10</a>]. In an observational study of 45 patients with UC and CDI, the colectomy rate at one year was higher in patients with CDI compared with age- and sex-matched controls (36 versus 10 percent) [<a href="#rid9">9</a>]. Management of CDI is discussed separately. (See  <a class="medical medical_review" href="/d/html/2698.html" rel="external">"<i>Clostridioides difficile</i> infection in adults: Treatment and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited endoscopic evaluation – </strong>For hospitalized patients with acute severe UC, we usually perform a limited lower endoscopy (eg, flexible sigmoidoscopy) without a bowel preparation to assess the severity of mucosal disease, and we obtain biopsies to exclude infection (eg, cytomegalovirus). (See  <a class="medical medical_review" href="/d/html/8305.html" rel="external">"Approach to the diagnosis of cytomegalovirus infection", section on 'Gastrointestinal disease'</a>.) </p><p></p><p class="bulletIndent1">Endoscopic features of severe UC include marked mucosal erythema, absent vascular pattern, friability, and erosions [<a href="#rid11">11,12</a>]. The colonic mucosa may also bleed spontaneously and exhibit frank ulceration. The endoscopic appearance of UC is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/4072.html" rel="external">"Endoscopic diagnosis of inflammatory bowel disease in adults", section on 'Differentiating ulcerative colitis from Crohn disease'</a>.)</p><p></p><p class="bulletIndent1">Complete colonoscopy (ie, endoscopic examination to the cecum) is avoided in hospitalized patients with severe colitis because of the increased risk of colonic dilation and perforation [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – Patients with acute severe UC should undergo plain abdominal radiography at presentation to determine if there is colonic dilation (diameter ≥5.5 cm) or toxic megacolon (colon diameter ≥6 cm and evidence of systemic toxicity). In addition, imaging features suggestive of severe colitis include thickened colonic wall and loss of haustral pattern. We also repeat plain abdominal imaging if the patient's clinical status deteriorates (eg, worsening abdominal distension). The management of toxic megacolon is discussed separately. (See  <a class="medical medical_review" href="/d/html/1381.html" rel="external">"Toxic megacolon"</a>.)</p><p></p><p class="bulletIndent1">We obtain cross sectional imaging (computed tomography scan) for patients with a suspected complication (eg, diffuse peritonitis resulting from colonic perforation), and the clinical manifestations and diagnosis of intestinal perforation are discussed separately. (See  <a class="medical medical_review" href="/d/html/15075.html" rel="external">"Overview of gastrointestinal tract perforation"</a>.)</p><p></p><p class="headingAnchor" id="H1133536041"><span class="h1">INPATIENT MANAGEMENT</span></p><p class="headingAnchor" id="H3428060875"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>The short-term treatment goal for patients with acute severe UC is to achieve hemodynamic stability and symptomatic improvement (fewer stools, less or no bleeding), while the long-term goals are to achieve clinical remission (ie, resolution of diarrhea and bleeding) and endoscopic remission by demonstrating complete mucosal healing [<a href="#rid4">4</a>]. Response to therapy in the acute setting can be determined by assessing symptoms and hemodynamic status, performing serial physical examinations (eg, less abdominal tenderness and/or distension), and obtaining laboratory testing (eg, C-reactive protein [CRP]). </p><p class="headingAnchor" id="H1183864952"><span class="h2">General supportive care</span><span class="headingEndMark"> — </span>Patients with acute severe UC are treated in an inpatient setting, and some patients may require critical care support if they are hemodynamically unstable upon presentation. Patients are given fluid and electrolyte replacement, and some may also require blood products. Initial management consists of medical therapy, although some patients may not respond and will need surgery during the index hospitalization. (See <a class="local">'Surgery'</a> below.)</p><p>Patients with acute severe UC require a multidisciplinary approach involving specialists in gastroenterology, surgery, and for some patients, critical care medicine [<a href="#rid14">14,15</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Inpatient care includes monitoring vital signs, performing physical examination (ie, assess for abdominal distension and tenderness), and tracking stool output (frequency, consistency, and presence of visible blood). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluids and electrolytes</strong> – Intravenous fluid and electrolyte replacement are necessary to correct and prevent dehydration or electrolyte imbalance. The approach to fluid resuscitation in hospitalized patients is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/98976.html" rel="external">"Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock", section on 'Hemodynamic support'</a> and  <a class="medical medical_review" href="/d/html/2296.html" rel="external">"Maintenance and replacement fluid therapy in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventing venous thromboembolism</strong> – Pharmacologic venous thromboembolism prophylaxis should be administered to reduce the risk of thromboembolism in patients hospitalized with severe UC [<a href="#rid16">16-18</a>]. Studies have demonstrated an increased risk of venous thromboembolism and pulmonary embolism in patients with inflammatory bowel disease in both population-based and hospital-based cohorts [<a href="#rid19">19-21</a>]. (See  <a class="medical medical_review" href="/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults", section on 'Our approach'</a> and  <a class="medical medical_review" href="/d/html/4344.html" rel="external">"Pulmonary complications of inflammatory bowel disease", section on 'Prophylaxis for venous thromboembolism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutrition</strong> – If patients with acute severe UC can tolerate oral intake, continuation of regular diet is appropriate; bowel rest tends to reduce stool volume but does not affect disease activity [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/d/html/13924.html" rel="external">"Nutrition and dietary management for adults with inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1">However, if patients have moderate to severe pain when they eat or if they cannot take in adequate calories, <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> may be required until clinical improvement allows for enteral feeding or until the patient goes to surgery. Enteral nutrition should also be stopped if a complication such as toxic megacolon is suspected (systemic toxicity and radiographic evidence of colonic dilation), and this is discussed separately. (See  <a class="medical medical_review" href="/d/html/1381.html" rel="external">"Toxic megacolon"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood products</strong> – Transfusion of packed red blood cells is typically needed if the hemoglobin is &lt;9 g/dL (90 g/L) for high-risk patients (eg, hemodynamically unstable) and if it is &lt;7 to 8 g/dL (70 to 80 g/L) in low-risk patients (eg, hemodynamically stable, no cardiovascular disease). Indications for red blood cell transfusions and risk assessment are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics –</strong> We do not routinely use broad-spectrum intravenous antibiotics for patients with acute severe UC; however, we do initiate antibiotic therapy for patients who have peritoneal signs, fever (temperature ≥37.8 degrees C), or who meet the criteria for either fulminant colitis or toxic megacolon. (See <a class="local">'Defining disease severity'</a> above and  <a class="medical medical_review" href="/d/html/1381.html" rel="external">"Toxic megacolon"</a>.) </p><p></p><p class="bulletIndent1">For these selected patients, broad-spectrum antibiotics (eg, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> and <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>) are given to reduce septic complications and in anticipation of peritonitis resulting from perforation. (See  <a class="medical medical_review" href="/d/html/101694.html" rel="external">"Antimicrobial approach to intra-abdominal infections in adults", section on 'Approach to empiric antibiotic selection'</a>.)</p><p></p><p class="bulletIndent1">Routine use of antibiotics does not increase the likelihood of responding to medical therapy or lower the colectomy rate [<a href="#rid24">24-27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications to avoid</strong> – The following medications are avoided in patients with acute severe UC:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All antimotility agents, opioids, and anticholinergic medications are avoided due to the risk of worsening ileus and precipitating toxic megacolon. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral 5-aminosalicylate (5-ASA) preparations are discontinued at the time of hospital admission because 5-ASA preparations are usually ineffective for inducing remission in patients with acute severe UC [<a href="#rid28">28</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonsteroidal anti-inflammatory medications are avoided because they have been associated with disease flares and inflammatory bowel disease (IBD)-related hospitalizations [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H1133540232"><span class="h2">Initial therapy</span><span class="headingEndMark"> — </span>Initial therapy for most patients with acute severe UC includes systemic and topical glucocorticoids; however, an anti-tumor necrosis factor (TNF) agent (<a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>) is an alternative initial treatment for some patients (eg, those who do not tolerate glucocorticoids). (See <a class="local">'Infliximab'</a> below.) </p><p class="headingAnchor" id="H1902015455"><span class="h3">Systemic glucocorticoids</span><span class="headingEndMark"> — </span>We begin intravenous glucocorticoid therapy as initial treatment for acute severe UC [<a href="#rid30">30</a>]. Regimens for intravenous glucocorticoid include <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> (16 to 20 mg intravenously [IV] every eight hours) or <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> (100 mg IV every eight hours). Methylprednisolone is preferred because that formulation is associated with less sodium-retention and potassium-wasting than hydrocortisone. Continuous infusions of intravenous glucocorticoids are not safer or more effective than bolus doses in achieving clinical remission in patients with severe UC [<a href="#rid31">31</a>].</p><p>Most patients who respond to intravenous glucocorticoids will have symptomatic improvement (ie, fewer stools and less bleeding) within three to five days after starting therapy. However, patients who have no clinical improvement within five to seven days of starting systemic glucocorticoids are unlikely to respond [<a href="#rid32">32,33</a>]. For patients who do not respond within five days, we initiate second-line therapy with either an anti-TNF agent or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>. (See <a class="local">'Failure to respond'</a> below.)</p><p>Treatment with intravenous glucocorticoids results in clinical improvement for some patients with severe UC. In a systematic review of 26 trials and cohort studies including 1429 adult patients who were hospitalized with severe UC and treated with intravenous glucocorticoids, 67 percent (95% CI 65-69) of patients achieved a clinical response [<a href="#rid34">34</a>]. In addition, data from randomized trials suggested that oral glucocorticoids were effective for inducing remission in patients with UC. In a meta-analysis of five trials including 445 patients with active UC, oral glucocorticoid therapy resulted in higher rates of achieving remission compared with placebo (46 versus 19 percent) [<a href="#rid35">35</a>]. </p><p class="headingAnchor" id="H2752842452"><span class="h3">Topical glucocorticoids</span><span class="headingEndMark"> — </span>In addition to intravenous glucocorticoids, we also use topical glucocorticoid therapy (eg, suppository, foam, or enema daily or twice daily) for patients with acute severe UC involving the distal colon because topical treatment may help provide symptomatic relief (eg, reduced fecal urgency, tenesmus)  (<a class="graphic graphic_table graphicRef86774" href="/d/graphic/86774.html" rel="external">table 1</a>) [<a href="#rid4">4</a>]. However, no randomized trials have examined the benefit of topical glucocorticoid therapy in this setting. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Ulcerative proctitis or proctosigmoiditis'</a>.)</p><p class="headingAnchor" id="H1684390864"><span class="h2">Failure to respond</span><span class="headingEndMark"> — </span>Patients with acute severe UC who fail to improve within three to five days of intravenous glucocorticoids are given either <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> as second-line medical therapy, or they undergo colectomy. </p><p class="headingAnchor" id="H2974546663"><span class="h3">Escalating medical therapy</span><span class="headingEndMark"> — </span>Medical therapy is escalated to either <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> for patients who do not respond to intravenous glucocorticoids after three to five days [<a href="#rid30">30</a>]. The decision to choose infliximab versus cyclosporine in hospitalized patients with acute, glucocorticoid-refractory UC depends upon several factors: patient characteristics and comorbidities (eg, hypertension, renal disease); hypersensitivity or allergy to infliximab, cyclosporine, and/or thiopurines; and patient and clinician preferences. Infliximab is commonly used in the management of both UC and Crohn disease, and clinicians may be more familiar with the dosing, monitoring, and adverse effects of anti-TNF agents compared with cyclosporine, which is used less frequently. The efficacy and safety are not significantly different between infliximab and cyclosporine for patients with acute severe UC refractory to intravenous glucocorticoids [<a href="#rid36">36-40</a>]. </p><p>Use of <a class="drug drug_general" data-topicid="87040" href="/d/drug information/87040.html" rel="external">tofacitinib</a>, an oral small molecule, for patients with acute severe UC has been reported in case series, although further studies are needed to establish its safety and dosing regimen in this setting [<a href="#rid41">41,42</a>]. (See  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Small molecules'</a>.) </p><p class="headingAnchor" id="H410982843"><span class="h4">Infliximab</span><span class="headingEndMark"> — </span>We typically use <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> for most patients with glucocorticoid-refractory acute severe UC, and we initially use standard induction dosing of infliximab (5 mg/kg at 0, 2, and 6 weeks). Patients typically demonstrate a clinical response (eg, hemodynamic stability, fewer stools, no bleeding) to infliximab within three to five days; the goal is induction of clinical remission. Specifically, patients should have &lt;6 formed stools, without associated blood, and should be able to resume oral intake without diarrhea or abdominal pain. </p><p>Patients who fail to respond to the initial <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> infusion within five days are usually given a second infliximab infusion at a dose of 10 mg/kg [<a href="#rid43">43</a>]. For patients who respond to the second infliximab infusion, we give the third induction infusion of infliximab in four weeks following the second induction dose. We generally reduce the infliximab dose to standard dosing (5 mg/kg) after clinical remission has been achieved, and we use infliximab for maintenance therapy. (See <a class="local">'Infliximab-responders'</a> below.) </p><p>Patients who do not respond to the second <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> infusion within five days are evaluated for colectomy. (See <a class="local">'Surgery'</a> below.)</p><p>Some of the patients who initially respond to <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> will eventually require surgery after the index hospitalization. Thus, it is important to discuss surgery as an option and to consult a colorectal surgeon to participate in both the initial and the long-term care of the patient [<a href="#rid44">44-46</a>]. (See  <a class="medical medical_review" href="/d/html/1375.html" rel="external">"Surgical management of ulcerative colitis"</a>.)</p><p>Pretreatment screening, dosing, monitoring, and adverse effects associated with anti-TNF agents are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p></p><p>Contraindications to the use of anti-TNF therapies (briefly summarized) include the following (see  <a class="medical medical_review" href="/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Use of TNF inhibitors'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Active uncontrolled infection </p><p class="bulletIndent1"><span class="glyph">●</span>Latent (untreated) tuberculosis</p><p class="bulletIndent1"><span class="glyph">●</span>Demyelinating disease (eg, multiple sclerosis, optic neuritis)</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure</p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy</p><p></p><p>We initially continue intravenous and topical glucocorticoids with the intent of eventually tapering all glucocorticoids. The approach to tapering glucocorticoids and providing maintenance therapy is discussed below. (See <a class="local">'Tapering glucocorticoids'</a> below and <a class="local">'Infliximab-responders'</a> below.)</p><p>Small trials and observational studies have demonstrated short- and long-term efficacy of <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> in patients with acute severe UC [<a href="#rid46">46-49</a>]. In a trial including 45 patients with acute severe UC, patients given infliximab had lower colectomy rates at three months compared with patients given placebo (30 versus 67 percent; odds ratio for colectomy in placebo group 4.9; 95% CI 1.4-17) [<a href="#rid47">47</a>]. In an observational study of 211 patients who were given infliximab for acute severe UC, the colectomy-free survival rates at 12 and 60 months were 64 and 53 percent, respectively [<a href="#rid49">49</a>].</p><p>Additional studies are needed to identify the optimal dosing regimen for <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> in acute severe UC. A retrospective study of 50 hospitalized patients with steroid-refractory, acute severe UC compared colectomy rates in patients who received standard infliximab dosing (at 0, 2, and 6 weeks) with an accelerated dosing regimen consisting of three induction doses of infliximab within a median period of 24 days [<a href="#rid50">50</a>]. Although colectomy rates during induction therapy were lower with the accelerated regimen compared with the standard regimen (7 versus 40 percent), there were no significant differences in colectomy rates between the two groups in the two-year follow-up period. </p><p class="headingAnchor" id="H1734888696"><span class="h4">Cyclosporine</span><span class="headingEndMark"> — </span>We use intravenous <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> for selected patients who are refractory to intravenous glucocorticoids as a short-term bridge to therapy with a slower onset, longer-acting medication (<a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a>). (See <a class="local">'Cyclosporine-responders'</a> below.)</p><p>However, we do <strong>not</strong> use <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> in patients with any of the following conditions:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension (blood pressure &gt;140/90 mmHg). </p><p class="bulletIndent1"><span class="glyph">●</span>Renal disease (serum creatinine &gt;1.4 mg/dL [124 microm/L]).</p><p class="bulletIndent1"><span class="glyph">●</span>History of seizure disorders.</p><p class="bulletIndent1"><span class="glyph">●</span>Low serum total cholesterol (&lt;120 mg/dL [3.11 mmol/L]).</p><p class="bulletIndent1"><span class="glyph">●</span>Low serum magnesium level.</p><p class="bulletIndent1"><span class="glyph">●</span>Low serum albumin (&lt;2.3 g/dL [23 g/L]) [<a href="#rid36">36</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Prior intolerance or failure of immunomodulator therapy (eg, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>). </p><p class="bulletIndent1"><span class="glyph">●</span>Prior failure of biologic agent (eg, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>) [<a href="#rid51">51</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Inability to comply with dosing and monitoring requirements while on <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>. </p><p></p><p>For patients with no contraindications to <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, we typically initiate a dose of 2 mg/kg intravenously daily (in two divided doses) because this dose is effective and is associated with less toxicity compared with a higher dose (4 mg/kg) [<a href="#rid52">52,53</a>]. Side effects and drug interactions with cyclosporine are common, and some may be life-threatening. Thus, patients receiving therapy must be carefully monitored for electrolyte abnormalities, nephrotoxicity, hypertension, neurotoxicity, and infections. Prophylaxis against <em>Pneumocystis </em>pneumonia during therapy is required. The side effects of cyclosporine, drug interactions, and strategies to minimize toxicity are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a> and  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a>.)</p><p>To achieve target <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> concentrations in patients with UC, blood levels of cyclosporine should be checked every one to two days after initiating therapy and after each dosing change, and then every two to three days when on stable doses. Clinical practice varies with regard to monitoring of cyclosporine levels; some experts have suggested aiming for trough levels &lt;300 ng/mL [<a href="#rid54">54</a>]. The dose can be increased in 0.5 mg/kg per day increments as tolerated to a maximum of 4 mg/kg per day. Doses can be rounded to the nearest 25 mg, to aid in subsequent conversion to oral cyclosporine.</p><p>Patients who respond to <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> typically have symptomatic improvement within two to three days, while the goal is resolution of symptoms. Specifically, patients should have &lt;6 formed stools, without associated blood, no abdominal pain, and should be able to eat, prior to converting intravenous formulation to oral cyclosporine microemulsion. Patients who fail to improve within three days are evaluated for colectomy [<a href="#rid33">33,55</a>]. </p><p>For patients who respond to intravenous <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, conversion to oral modified cyclosporine (a microemulsion formulation) is calculated by doubling the intravenous dose that had led to adequate levels, administered in divided doses 12 hours apart. For example, patients who had a good response at levels of 4 mg/kg per day of intravenous cyclosporine would be converted to 8 mg/kg per day of oral modified cyclosporine, delivered as 4 mg/kg every 12 hours. Steady state is achieved after the third dose; trough levels are checked immediately prior to fourth dose, with a goal level of 200 ng/mL to 300 ng/mL. Cyclosporine levels &lt;200 ng/mL have been associated with loss of response [<a href="#rid54">54</a>].</p><p>We initially continue intravenous and topical glucocorticoids with the intent of eventually tapering all glucocorticoids. The approach to tapering <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> and glucocorticoids and initiating long-term maintenance therapy is discussed below. (See <a class="local">'Cyclosporine-responders'</a> below and <a class="local">'Tapering glucocorticoids'</a> below.)</p><p>Short-term efficacy of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> has been demonstrated in small trials [<a href="#rid56">56-58</a>]. In a trial including 20 patients with glucocorticoid-refractory severe colitis, clinical response occurred in 9 of 11 patients given cyclosporine compared with none of the patients given placebo [<a href="#rid56">56</a>]. However, long-term follow-up studies suggest that the long-term risk of colectomy (despite initial clinical remission) ranges from 35 to 58 percent [<a href="#rid56">56,59</a>].</p><p class="headingAnchor" id="H3908788242"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>For patients with acute severe UC who fail to respond to intravenous glucocorticoids and either anti-TNF therapy or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, surgery (eg, total abdominal colectomy with end ileostomy) is indicated. In addition, patients who develop one or more life-threatening complications (eg, colonic perforation, toxic megacolon, severe hematochezia with hemodynamic instability) require urgent surgery. The indications for surgery and specific surgical options for patients with UC are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/1375.html" rel="external">"Surgical management of ulcerative colitis"</a>.)</p><p class="headingAnchor" id="H725106677"><span class="h2">Complications</span></p><p class="headingAnchor" id="H3914879494"><span class="h3">Fulminant ulcerative colitis</span><span class="headingEndMark"> — </span>Patients with acute severe UC may progress to fulminant UC (or patients may present initially with fulminant colitis). The management of patients with fulminant UC is similar to treatment of patients with acute severe UC with the following additions (see <a class="local">'Defining disease severity'</a> above and <a class="local">'Inpatient management'</a> above): </p><p class="bulletIndent1"><span class="glyph">●</span>Patients with fulminant colitis are typically monitored in a critical care setting and followed closely with vital signs and physical examination every four to six hours to evaluate for signs of peritonitis. A complete blood count, serum electrolytes, serum albumin, liver biochemical tests, and CRP are checked every 12 to 24 hours. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial management of patients with fulminant UC includes bowel rest, intravenous fluids, broad-spectrum antibiotics, in addition to intravenous and topical glucocorticoids. (See <a class="local">'Initial therapy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who do not respond to initial treatment with glucocorticoids within three days are treated with either <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>. If the patient does not respond to second-line medical therapy within three days, colectomy is typically performed. (See <a class="local">'Failure to respond'</a> above.)</p><p></p><p class="headingAnchor" id="H4070361935"><span class="h3">Toxic megacolon</span><span class="headingEndMark"> — </span>Toxic megacolon is a potentially lethal complication of IBD, especially UC, that is characterized by nonobstructive colonic dilatation plus systemic toxicity. The diagnosis and management of toxic megacolon is discussed separately. (See  <a class="medical medical_review" href="/d/html/1381.html" rel="external">"Toxic megacolon"</a>.)</p><p class="headingAnchor" id="H173927463"><span class="h3">Colonic perforation</span><span class="headingEndMark"> — </span>Patients with UC who develop colonic perforation require colectomy, although this complication is rare. Colonic perforation and surgical management of UC are discussed separately. (See  <a class="medical medical_review" href="/d/html/15075.html" rel="external">"Overview of gastrointestinal tract perforation"</a> and  <a class="medical medical_review" href="/d/html/1375.html" rel="external">"Surgical management of ulcerative colitis"</a>.)</p><p class="headingAnchor" id="H3520343120"><span class="h1">TRANSITION TO OUTPATIENT CARE</span></p><p class="headingAnchor" id="H3260781662"><span class="h2">Criteria for discharge</span><span class="headingEndMark"> — </span>Most patients with severe UC have symptomatic improvement after receiving either first- or second-line medical therapy (eg, intravenous glucocorticoids with or without a second-line agent [eg, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>]). Hospitalized patients are reassessed daily to determine if they are eligible to be discharged. While achieving clinical remission is not a requirement, patients must meet all criteria listed below before they can be discharged from the hospital:</p><p class="bulletIndent1"><span class="glyph">●</span>Normalization of vital signs (ie, resolution of fever, tachycardia, or hypotension)</p><p class="bulletIndent1"><span class="glyph">●</span>&lt;6 stools per day with no or small amounts of blood with each bowel movement</p><p class="bulletIndent1"><span class="glyph">●</span>Resolution of severe abdominal pain</p><p class="bulletIndent1"><span class="glyph">●</span>Tolerance of oral diet </p><p></p><p class="headingAnchor" id="H3134275269"><span class="h2">Tapering glucocorticoids</span><span class="headingEndMark"> — </span>We discontinue intravenous glucocorticoids and begin an oral formulation (<a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 60 mg by mouth daily) prior to hospital discharge. Oral glucocorticoids are not used for long-term maintenance, and a medication taper is usually started two weeks after symptoms improve (ie, &lt;6 stools daily, no or minimal blood, no abdominal pain). We typically taper prednisone by decreasing the dose by 5 to 10 mg every week until a daily dose of 20 mg is reached, and then by 2.5 mg every week until it is discontinued [<a href="#rid60">60</a>]. Topical glucocorticoids are also gradually tapered, and this is discussed separately. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Alternative therapy'</a>.)</p><p>While glucocorticoids induce remission for some patients with severe UC, they are not used for maintenance therapy because of the adverse effects associated with long-term use [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H324559250"><span class="h1">MAINTAINING REMISSION</span></p><p class="headingAnchor" id="H3147304920"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>The goal of management for patients in remission is to maintain glucocorticoid-free remission and prevent clinical and endoscopic relapse. After achieving clinical remission (ie, resolution of diarrhea and bleeding), colonoscopy is typically performed in 6 to 12 months to assess for mucosal healing. Additional monitoring (eg, laboratory studies) for patients with UC in remission is discussed separately. (See  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Monitoring'</a>.)</p><p class="headingAnchor" id="H3413029226"><span class="h2">Selecting a therapy</span><span class="headingEndMark"> — </span>For patients who respond to medical therapy, the choice of maintenance therapy depends primarily on response to induction therapy, but it also may depend on patient preferences, clinician preferences, and insurance coverage/cost.</p><p class="headingAnchor" id="H4291297397"><span class="h3">Glucocorticoid-responders</span><span class="headingEndMark"> — </span>Options for maintenance therapy for patients who responded to systemic glucocorticoids include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-tumor necrosis factor (TNF) agent</strong> – An anti-TNF agent (eg, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>) with or without a thiopurine is used as maintenance therapy for most patients who achieve clinical remission with intravenous glucocorticoids [<a href="#rid62">62,63</a>]. (See <a class="local">'Infliximab-responders'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thiopurine monotherapy</strong> – Thiopurine monotherapy (ie, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> [AZA] or <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a> [6-MP]) may be used as an alternative to an anti-TNF-based regimen for maintaining remission [<a href="#rid64">64</a>]. The pretreatment screening, dosing, safety, and monitoring of AZA and 6-MP are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/d/html/4058.html" rel="external">"Thiopurines: Pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1">The efficacy of thiopurine monotherapy for maintaining remission for patients with UC is discussed separately. (See  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Maintenance of remission'</a>.)</p><p></p><p class="headingAnchor" id="H2616085131"><span class="h3">Infliximab-responders</span><span class="headingEndMark"> — </span>Patients who achieve clinical remission with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> are generally continued on infliximab for maintenance therapy, and for most patients, a thiopurine (ie, AZA) is added to the drug regimen upon hospital discharge [<a href="#rid62">62,63</a>]. The thiopurine is generally given for six months after clinical remission has been achieved, and then the thiopurine is stopped, while continuing anti-TNF agent monotherapy for long-term maintenance. </p><p>However, for young, male patients (age &lt;30 years), we use anti-TNF agent monotherapy for maintaining remission. We avoid combination therapy that includes a thiopurine because of the risk of hepatosplenic T-cell lymphoma in such patients, and this is discussed separately. (See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Hepatosplenic T-cell lymphoma'</a>.)</p><p>The pretreatment screening, maintenance dosing, monitoring, and safety of anti-TNF agents and thiopurines are discussed separately. (See  <a class="medical medical_review" href="/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults"</a> and  <a class="medical medical_review" href="/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease"</a>.)</p><p>The efficacy of anti-TNF agents as maintenance monotherapy is established, but the data supporting combination therapy (ie, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> plus a thiopurine) are more limited [<a href="#rid46">46,63,65-67</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-TNF monotherapy</strong> – For patients with active UC who responded to anti-TNF induction therapy, anti-TNF agents are effective for maintaining remission [<a href="#rid46">46,65,66</a>]. In a meta-analysis of three trials including 1070 patients with UC, patients on anti-TNF therapy were more likely to maintain remission compared with placebo (relative risk 2.00; 95% CI 1.52-2.62) [<a href="#rid66">66</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-TNF agent plus thiopurine</strong> – In a trial of 239 patients with moderate to severe UC, patients treated with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> plus <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> had higher rates of glucocorticoid-free clinical remission at 16 weeks compared with patients treated with infliximab monotherapy or azathioprine monotherapy (40 versus 24 and 22 percent, respectively) [<a href="#rid63">63</a>]. However, the rates of mucosal healing (defined as a Mayo endoscopy subscore of 0 or 1) were not significantly different for patients on combination therapy compared with patients on infliximab alone. (See  <a class="medical medical_review" href="/d/html/4072.html" rel="external">"Endoscopic diagnosis of inflammatory bowel disease in adults", section on 'Differentiating ulcerative colitis from Crohn disease'</a>.)</p><p></p><p class="headingAnchor" id="H4220449732"><span class="h3">Cyclosporine-responders</span><span class="headingEndMark"> — </span>Patients who respond to intravenous <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> are transitioned to oral modified cyclosporine (a microemulsion formulation), and the outpatient regimen also includes <em>Pneumocystis </em>pneumonia prophylaxis, a thiopurine, and glucocorticoid taper, followed by cyclosporine taper:</p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'Cyclosporine'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'Tapering glucocorticoids'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a>.)</p><p></p><p>For long-term maintenance therapy, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> (or <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a>) is started. The pretreatment screening, administration, safety, and monitoring of thiopurines are discussed separately. (See  <a class="medical medical_review" href="/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/d/html/4058.html" rel="external">"Thiopurines: Pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease"</a>.)</p><p>The efficacy of thiopurine monotherapy for maintaining remission for patients with UC is discussed separately. (See  <a class="medical medical_review" href="/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Maintenance of remission'</a>.)</p><p>After the glucocorticoid taper has been completed, oral <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> is tapered to discontinuation by reducing the dose once per week in four (approximately) equal increments. Patients who achieve remission with cyclosporine but who cannot maintain remission on thiopurine monotherapy in the absence of glucocorticoids and cyclosporine are evaluated for surgery. (See  <a class="medical medical_review" href="/d/html/1375.html" rel="external">"Surgical management of ulcerative colitis"</a>.)</p><p class="headingAnchor" id="H182638267"><span class="h1">NUTRITION</span><span class="headingEndMark"> — </span>The use of nutrition and dietary therapy in patients with inflammatory bowel disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/13924.html" rel="external">"Nutrition and dietary management for adults with inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H685874277"><span class="h1">HEALTH MAINTENANCE</span><span class="headingEndMark"> — </span>It is important to address routine health maintenance, including screening and prevention of other diseases as well as monitoring for side effects of therapy in patients with inflammatory bowel disease (IBD). Patients with longstanding IBD affecting the colon also require endoscopic surveillance for dysplasia. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Health maintenance'</a> and  <a class="medical medical_review" href="/d/html/4079.html" rel="external">"Surveillance and management of dysplasia in patients with inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H2292470567"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109937.html" rel="external">"Society guideline links: Ulcerative colitis in adults"</a>.)</p><p class="headingAnchor" id="H28707118"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15613.html" rel="external">"Patient education: Ulcerative colitis in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1991.html" rel="external">"Patient education: Ulcerative colitis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2018.html" rel="external">"Patient education: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation </strong>– Therapy for UC is guided by pretreatment evaluation (ie, laboratory studies, lower endoscopy, imaging), and the goals are to exclude alternative or co-existing conditions and determine the extent and severity of disease. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defining disease severity </strong>– In clinical practice, acute severe UC can be defined by the following. (See <a class="local">'Defining disease severity'</a> above.):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bloody stool frequency ≥6 per day</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PLUS at least one of the following (ie, evidence of systemic toxicity):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Fever (temperature ≥37.8°C)</p><p class="bulletIndent3"><span class="glyph">-</span>Tachycardia (heart rate [HR] ≥90 beats/minute)</p><p class="bulletIndent3"><span class="glyph">-</span>Anemia (hemoglobin &lt;10.5 g/dL [105 g/L])</p><p class="bulletIndent3"><span class="glyph">-</span>Elevated inflammatory marker (eg, C-reactive protein)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inpatient management </strong>–<strong> </strong>Patients with acute severe UC are managed with inpatient hospitalization, monitoring, fluid and electrolyte replacement, and they may require blood products. (See <a class="local">'General supportive care'</a> above.)</p><p></p><p class="bulletIndent1">Patients are initially managed with medical therapy, although some patients will need surgery during the index hospitalization:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy</strong> – For patients with acute severe UC, we recommend intravenous glucocorticoid therapy as initial treatment to induce remission  (<a class="graphic graphic_algorithm graphicRef123047" href="/d/graphic/123047.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We also use topical glucocorticoid therapy because topical treatment may provide symptomatic relief (eg, reduced fecal urgency, tenesmus). (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Escalating medical therapy</strong> – For patients with acute severe UC who fail to respond to intravenous glucocorticoid therapy in five days, we initiate second-line therapy with either <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>. Selecting a second-line agent depends on patient characteristics, patient preferences, and clinician preference. (See <a class="local">'Escalating medical therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transition to outpatient care</strong> – For patients with acute severe UC who have symptomatic improvement with medical therapy, the following criteria should be met prior to hospital discharge. (See <a class="local">'Transition to outpatient care'</a> above.):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normalization of vital signs (ie, resolution of fever, tachycardia, or hypotension)</p><p class="bulletIndent2"><span class="glyph">•</span>&lt;6 stools per day with no or small amounts of blood with each bowel movement</p><p class="bulletIndent2"><span class="glyph">•</span>Resolution of severe abdominal pain</p><p class="bulletIndent2"><span class="glyph">•</span>Tolerance of oral diet </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintaining remission</strong> – For patients with acute severe UC who achieve clinical remission with medical therapy, we suggest long-term medical therapy for maintaining remission. The choice of maintenance therapy depends primarily on the specific agent used to achieve remission, and it also depends on patient preferences, clinician preferences, and insurance coverage/cost. Commonly used maintenance therapy regimens include an anti-tumor necrosis factor (TNF) agent with a thiopurine, anti-TNF agent monotherapy, or thiopurine monotherapy. (See <a class="local">'Maintaining remission'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – The management of fulminant UC is similar to the management of acute severe UC with the following additional measures: bowel rest (nothing by mouth), empiric, intravenous broad-spectrum antibiotics, and lower threshold for surgical intervention (ie, no clinical improvement after three days of glucocorticoid therapy and three days of second-line therapy). (See <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1">Toxic megacolon is a potentially lethal complication of severe UC that is characterized by nonobstructive colonic dilation plus systemic toxicity. The diagnosis and management of toxic megacolon is discussed separately. (See  <a class="medical medical_review" href="/d/html/1381.html" rel="external">"Toxic megacolon"</a>.)</p><p></p><p class="headingAnchor" id="H1772975751"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">TRUELOVE SC, WITTS LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2:1041.</a></li><li><a class="nounderline abstract_t">Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317:1625.</a></li><li><a class="nounderline abstract_t">Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 Suppl A:5A.</a></li><li><a class="nounderline abstract_t">Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol 2019; 114:384.</a></li><li><a class="nounderline abstract_t">Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007; 52:2063.</a></li><li><a class="nounderline abstract_t">Prantera C, Davoli M, Lorenzetti R, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988; 10:41.</a></li><li><a class="nounderline abstract_t">Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:661.</a></li><li><a class="nounderline abstract_t">Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010; 55:415.</a></li><li><a class="nounderline abstract_t">Navaneethan U, Mukewar S, Venkatesh PG, et al. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohns Colitis 2012; 6:330.</a></li><li><a class="nounderline abstract_t">Murthy SK, Steinhart AH, Tinmouth J, et al. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther 2012; 36:1032.</a></li><li><a class="nounderline abstract_t">Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43:29.</a></li><li><a class="nounderline abstract_t">Waterman M, Knight J, Dinani A, et al. Predictors of Outcome in Ulcerative Colitis. Inflamm Bowel Dis 2015; 21:2097.</a></li><li><a class="nounderline abstract_t">Makkar R, Bo S. Colonoscopic perforation in inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2013; 9:573.</a></li><li><a class="nounderline abstract_t">Murthy SK, Steinhart AH, Tinmouth J, et al. Impact of gastroenterologist care on health outcomes of hospitalised ulcerative colitis patients. Gut 2012; 61:1410.</a></li><li><a class="nounderline abstract_t">Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68:s1.</a></li><li><a class="nounderline abstract_t">Carter MJ, Lobo AJ, Travis SP, IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 Suppl 5:V1.</a></li><li><a class="nounderline abstract_t">Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.</a></li><li><a class="nounderline abstract_t">Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 2005; 3:617.</a></li><li><a class="nounderline abstract_t">Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60:937.</a></li><li><a class="nounderline abstract_t">Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53:542.</a></li><li><a class="nounderline abstract_t">Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103:2272.</a></li><li><a class="nounderline abstract_t">Dickinson RJ, Ashton MG, Axon AT, et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980; 79:1199.</a></li><li><a class="nounderline abstract_t">McIntyre PB, Powell-Tuck J, Wood SR, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986; 27:481.</a></li><li><a class="nounderline abstract_t">Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27:1210.</a></li><li><a class="nounderline abstract_t">Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89:43.</a></li><li><a class="nounderline abstract_t">Mantzaris GJ, Petraki K, Archavlis E, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001; 36:971.</a></li><li><a class="nounderline abstract_t">Dickinson RJ, O'Connor HJ, Pinder I, et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985; 26:1380.</a></li><li><a class="nounderline abstract_t">Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10:CD000543.</a></li><li><a class="nounderline abstract_t">Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4:196.</a></li><li><a class="nounderline abstract_t">Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020; 158:1450.</a></li><li><a class="nounderline abstract_t">Bossa F, Fiorella S, Caruso N, et al. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol 2007; 102:601.</a></li><li><a class="nounderline abstract_t">Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10:831.</a></li><li><a class="nounderline abstract_t">Travis S, Satsangi J, Lémann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut 2011; 60:3.</a></li><li><a class="nounderline abstract_t">Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5:103.</a></li><li><a class="nounderline abstract_t">Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:590.</a></li><li><a class="nounderline abstract_t">Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380:1909.</a></li><li><a class="nounderline abstract_t">Ordás I, Domènech E, Mañosa M, et al. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. Am J Gastroenterol 2017; 112:1709.</a></li><li><a class="nounderline abstract_t">Seagrove AC, Alam MF, Alrubaiy L, et al. Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT). BMJ Open 2014; 4:e005091.</a></li><li><a class="nounderline abstract_t">Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2017.</a></li><li><a class="nounderline abstract_t">Song EM, Oh EH, Hwang SW, et al. Comparison of outcomes of cyclosporine A and infliximab for steroid-refractory acute severe ulcerative colitis. J Gastroenterol Hepatol 2021; 36:2463.</a></li><li><a class="nounderline abstract_t">Berinstein JA, Steiner CA, Regal RE, et al. Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2019; 17:988.</a></li><li><a class="nounderline abstract_t">Berinstein JA, Sheehan JL, Dias M, et al. Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study. Clin Gastroenterol Hepatol 2021; 19:2112.</a></li><li><a class="nounderline abstract_t">Hindryckx P, Novak G, Vande Casteele N, et al. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther 2017; 45:617.</a></li><li><a class="nounderline abstract_t">Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121:255.</a></li><li><a class="nounderline abstract_t">Baudet A, Rahmi G, Bretagne AL, et al. Severe ulcerative colitis: present medical treatment strategies. Expert Opin Pharmacother 2008; 9:447.</a></li><li><a class="nounderline abstract_t">Gustavsson A, Järnerot G, Hertervig E, et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010; 32:984.</a></li><li><a class="nounderline abstract_t">Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128:1805.</a></li><li><a class="nounderline abstract_t">Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7:83.</a></li><li><a class="nounderline abstract_t">Sjöberg M, Magnuson A, Björk J, et al. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther 2013; 38:377.</a></li><li><a class="nounderline abstract_t">Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13:330.</a></li><li><a class="nounderline abstract_t">Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008; 6:1112.</a></li><li><a class="nounderline abstract_t">Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125:1025.</a></li><li><a class="nounderline abstract_t">Rayner CK, McCormack G, Emmanuel AV, Kamm MA. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003; 18:303.</a></li><li><a class="nounderline abstract_t">Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94:1587.</a></li><li><a class="nounderline abstract_t">Saito K, Katsuno T, Nakagawa T, et al. Predictive factors of response to intravenous ciclosporin in severe ulcerative colitis: the development of a novel prediction formula. Aliment Pharmacol Ther 2012; 36:744.</a></li><li><a class="nounderline abstract_t">Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4:760.</a></li><li><a class="nounderline abstract_t">Campbell S, Ghosh S. Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome. Dig Liver Dis 2003; 35:546.</a></li><li><a class="nounderline abstract_t">Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841.</a></li><li><a class="nounderline abstract_t">Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005; 17:79.</a></li><li class="breakAll">Taylor K, Gibson PR.. Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach, C. Baumgart, Daniel (Eds), 2017.</li><li><a class="nounderline abstract_t">Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012; 107:1409.</a></li><li><a class="nounderline abstract_t">Bitton A, Buie D, Enns R, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol 2012; 107:179.</a></li><li><a class="nounderline abstract_t">Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146:392.</a></li><li><a class="nounderline abstract_t">Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; :CD000478.</a></li><li><a class="nounderline abstract_t">Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014; 160:704.</a></li><li><a class="nounderline abstract_t">Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2014; 39:660.</a></li><li><a class="nounderline abstract_t">Armuzzi A, Pugliese D, Danese S, et al. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2014; 20:1368.</a></li></ol></div><div id="topicVersionRevision">Topic 4068 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13260656" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cortisone in ulcerative colitis; final report on a therapeutic trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3317057" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16151544" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30840605" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : ACG Clinical Guideline: Ulcerative Colitis in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17436102" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3356884" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472532" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : C-reactive protein as a marker for inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19255850" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22405170" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23061526" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9771402" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A simple clinical colitis activity index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26177304" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Predictors of Outcome in Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24729766" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Colonoscopic perforation in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22684482" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Impact of gastroenterologist care on health outcomes of hospitalised ulcerative colitis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31562236" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15306569" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Guidelines for the management of inflammatory bowel disease in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574271" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16206491" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Thrombosis and inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339206" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15016749" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18684186" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6777233" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3084344" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Controlled trial of bowel rest in the treatment of severe acute colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3536677" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8273796" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11521989" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3910524" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076889" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16469680" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31945371" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17156148" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9831403" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148578" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17142106" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21407179" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23063316" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28675163" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24785401" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28053054" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33783045" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comparison of outcomes of cyclosporine A and infliximab for steroid-refractory acute severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30458248" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34048936" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28074618" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Review article: dose optimisation of infliximab for acute severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11487534" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18220494" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Severe ulcerative colitis: present medical treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20937043" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15940615" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11383595" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23799948" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25086187" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18928936" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14517785" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12895214" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10364029" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Intravenous cyclosporin in ulcerative colitis: a five-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22957944" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Predictive factors of response to intravenous ciclosporin in severe ulcerative colitis: the development of a novel prediction formula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16716758" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14567458" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8196726" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cyclosporine in severe ulcerative colitis refractory to steroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15647646" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Ciclosporin use in acute ulcerative colitis: a long-term experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15647646" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Ciclosporin use in acute ulcerative colitis: a long-term experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22890223" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22108451" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24512909" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972046" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24842416" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24506179" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24983979" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
